<DOC>
	<DOC>NCT02197221</DOC>
	<brief_summary>Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma patients, non-progressive after induction therapy.</brief_summary>
	<brief_title>Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Must have results from their initial diagnosis available at the time of screening to confirm all the following : 1. Diagnosis of multiple myeloma according to the diagnostic 2. Symptomatic de novo Multiple Myeloma Be eligible for highdose therapy with autologous stem cell transplantation Autologous cell graft with a total number of CD 34 cells &gt; or = 5 X 106/kg before freezing Progressive disease Females participants pregnant or breastfeeding A known infection by the human immunodeficiency virus An active viral hepatitis B or C Unstable angina or myocardial infarction within 4 months prior to inclusion, heart failure NYHA class III or IV angina, uncontrolled, history of severe coronary artery disease, an uncontrolled serious ventricular arrhythmia, a sick sinus syndrome, or electrocardiographic evidence of acute ischemia or conduction disturbances grade 3 unless the patient has a pacemaker Uncontrolled hypertension or uncontrolled diabetes within 14 days before enrollment A history of another malignancy. If cancer was diagnosed more than 10 years and considered as cured, an authorization may be requested on a casebycase basis after discussion with the principal investigator A significant neuropathy of grade 34 or grade 2 with pain in the 14 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>